HSTOQ (Histogen) Other Stockholders Equity: $0.00 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTOQ Histogen Inc HSTOQ
12 GF Score
Price $0.00
View Full Analysis

What is Histogen Other Stockholders Equity?

Histogen HSTOQ +316.67% 12 Other Stockholders Equity is $0.00 Mil as of Sep. 2023. GuruFocus rates HSTOQ with a GF Score™ of 12/100.

Histogen's Other Stockholders Equity for the quarter that ended in Sep. 2023 was $0.00 Mil.

Histogen's quarterly Other Stockholders Equity increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) and increased from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Histogen's annual Other Stockholders Equity increased from Dec. 2020 ($-0.00 Mil) to Dec. 2021 ($0.00 Mil) but then declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil).

Histogen Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Histogen's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Histogen Other Stockholders Equity Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
0.00 -0.00 0.00 -0.00

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
HSTOQ
12GF Score
Histogen Inc HSTOQ
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Histogen Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Histogen (HSTOQ) has a Other Stockholders Equity of $0.00 Mil as of Sep. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Histogen and its competitors.
Is Histogen's Other Stockholders Equity too high?
Histogen's current Other Stockholders Equity is $0.00 Mil. Overall, Histogen has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Histogen's Other Stockholders Equity compare to GLMD and BLCM?
Histogen's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Histogen and its competitors. Histogen's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Histogen stock overvalued right now?
Histogen (HSTOQ) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Histogen's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Histogen (HSTOQ), the current Other Stockholders Equity is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Histogen Business Description

Address 10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
12GF Score

Get the complete analysis for HSTOQ

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price